Etrasimod

Etrasimod is an orally bioavailable and potent antagonist of sphingosine-1-phosphate (S1P) receptors with EC50 values of 0.093, 0.44, 0.32, 0.34, and 0.32 nM for human, mouse, rat, dog, and monkey S1P1 receptors. It is selective for S1P1, S1P4, and S1P5 receptors with EC50 values of 6.1, >10,000, >10,000, 147, and 24.4 nM for S1P1-5, respectively, in a beta-arrestin assay. Etrasimod (1 mg/kg, i.v.) decreases peripheral lymphocytes in mouse, rat, dog, and monkey (IC50s = 101, 51, 58, and 98 nM, respectively). It delays or prevents the onset and severity of murine experimental autoimmune encephalomyelitis (EAE) when administered at 0.3, 1, or 3 mg/kg. It also leads to lower EAE disease scores relative to vehicle when administered after disease onset and is efficacious in a rat model of collagen-induced arthritis.Formal Name: (3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydro-cyclopent[b]indole-3-acetic acid. CAS Number: 1206123-37-6. Synonyms: APD334. Molecular Formula: C26H26F3NO3. Formula Weight: 457.5. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml, Ethanol: 12.5 mg/ml. lambdamax: 227, 279 nm. SMILES: OC(C[C@H]1CCC2=C1NC3=CC=C(OCC4=CC=C(C5CCCC5)C(C(F)(F)F)=C4)C=C32)=O. InChi Code: InChI=1S/C26H26F3NO3/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)/t17-/m1/s1. InChi Key: MVGWUTBTXDYMND-QGZVFWFLSA-N.